JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akabani, G.
Right arrow Articles by Zalutsky, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akabani, G.
Right arrow Articles by Zalutsky, M. R.
Journal of Nuclear Medicine Vol. 44 No. 5 792-805
© 2003 by Society of Nuclear Medicine


Basic Science Investigations

Microdosimetric Analysis of {alpha}-Particle-Emitting Targeted Radiotherapeutics Using Histological Images

Gamal Akabani, PhD1, Stephen J. Kennel, PhD2 and Michael R. Zalutsky, PhD1

1 Department of Radiology, Duke University Medical Center, Durham, North Carolina
2 Life Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee

The purpose of this study was to evaluate the therapeutic efficacy and limitations of {alpha}-particle-emitting radiolabeled compounds by means of 2-dimensional histological images and distribution of activity on a microscopic level. Methods: A microdosimetric approach based on histological images is used to analyze the therapeutic effectiveness of {alpha}-particle-emitting 211At and 213Bi conjugated to 201B monoclonal antibody (mAb), which is reactive with murine lung blood vessels for the treatment of EMT-6 lung tumor colonies in nude mice. Autoradiography images were used to define the tissue morphology and activity distribution within lung tissues. Two animal groups were studied: Group A consisted of animals bearing small tumors (<130 µm) and group B consisted of larger tumors (<600 µm). Probability density functions (pdf) described the variability in average absorbed dose and survival probability among normal and tumor target cells and, in turn, were used to assess the survival fraction of tumor and normal tissue. Results: The average absorbed dose to tumor cells per unit cumulated activity concentration for animals in group A was 1.10 x 10-3 and 1.37 x 10-3 Gy g MBq-1 s-1 for 211At and 213Bi, respectively, and for animals in group B was 3.8 x 10-4 and 5.6 x 10-4 Gy g MBq-1 s-1 for 211At and 213Bi, respectively. The fraction of tumor cells that received a zero absorbed dose for animals in group A was 0.04% for 213Bi and 0.2% for 211At and for animals in group B was 25% for 213Bi and 31% for 211At. Both 213Bi- and 211At-labeled 201B mAb were effective therapies for animals with small tumors, where predicted therapeutic effectiveness was consistent with experimental findings; however, they were ineffective for animals with larger tumors. Conclusion: Microdosimetric methods based on knowledge of tissue morphology and activity distribution on a small-scale level can be a useful tool for evaluating a priori the therapeutic efficacy and limitations of targeted {alpha}-particle endoradiotherapeutic strategies.

Key Words: targeted radiotherapy • radioimmunotherapy • {alpha}-particle • 213Bi • 211At • autoradiography




This article has been cited by other articles:


Home page
JNMHome page
P. V.S.V. Neti and R. W. Howell
Lognormal Distribution of Cellular Uptake of Radioactivity: Statistical Analysis of {alpha}-Particle Track Autoradiography
J. Nucl. Med., June 1, 2008; 49(6): 1009 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Radiat Prot DosimetryHome page
R. W. Howell, P. V. S. V. Neti, M. Pinto, B. I. Gerashchenko, V. R. Narra, and E. I. Azzam
Challenges and progress in predicting biological responses to incorporated radioactivity
Radiat Prot Dosimetry, December 1, 2006; 122(1-4): 521 - 527.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. A. Rizzieri, G. Akabani, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, et al.
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
Blood, August 1, 2004; 104(3): 642 - 648.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. Carlin, G. Akabani, and M. R. Zalutsky
In Vitro Cytotoxicity of 211At-Astatide and 131I-Iodide to Glioma Tumor Cells Expressing the Sodium/Iodide Symporter
J. Nucl. Med., November 1, 2003; 44(11): 1827 - 1838.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.